China's Jiangsu Hengrui signs licensing deal with Braveheart Bio for heart drug (South China Morning Post) - Sep 5, 2025 - "The deal gives Braveheart Bio exclusive worldwide rights to develop, manufacture and commercialise the drug...HRS-1893...outside mainland China, Hong Kong, Macau and Taiwan. Jiangsu Hengrui will receive an initial payment totalling US$75 million, which includes cash, Braveheart Bio shares and a near-term milestone payment of up to US$10 million."
Licensing / partnership • Obstructive Hypertrophic Cardiomyopathy
|